Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2025-06-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于向控股子公司提供财务资助的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the provision of financial assistance (a loan) by the parent company to its controlling subsidiary. It details the loan amount, terms, board approval, shareholder structure, financial indicators of the subsidiary, risk analysis, and board opinions. The document is a formal disclosure of a financing activity related to capital allocation within the corporate group. It is not a full financial report, audit report, or earnings release. It is not a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it concerns a financing transaction and capital provision to a subsidiary. The document length is about 4552 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report. Therefore, the classification is CAP with high confidence.
2025-06-13 Chinese
中国银河证券股份有限公司关于瑞普生物股份有限公司拟转让控股子公司股权暨募投项目转让的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the proposed transfer of controlling equity in a subsidiary company (湖南中岸生物药业有限公司) by 瑞普生物股份有限公司. It includes extensive information about the transaction overview, the parties involved, financial data of the subsidiary, the use of raised funds, board and supervisory committee approvals, and the opinions of the sponsor institution. The document references regulatory frameworks and compliance with stock exchange rules, and it discusses the impact on the company's consolidated financial statements. The document is lengthy (over 11,000 characters) and contains substantive financial and operational details about the transaction and its implications. It is not a full annual or interim report, nor is it a simple announcement or certification. It is a comprehensive disclosure about a capital transaction involving a subsidiary and fundraising project transfer. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as equity transfers and related investment projects.
2025-06-13 Chinese
2024年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an "权益分派实施公告" which translates to "Implementation Announcement of Equity Distribution" for the fiscal year 2024. It details the dividend distribution plan, including the cash dividend per share, the total dividend amount, the record date, and the ex-dividend date. It also references the approval of the dividend plan at the 2024 Annual General Meeting held on April 24, 2025. The document is an announcement of the dividend amount and related implementation details rather than the dividend report itself. The document length is 2943 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of "Notice of Dividend Amount" (DIV).
2025-05-14 Chinese
2025年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2025 second extraordinary general meeting of shareholders of 瑞普生物股份有限公司. It details the meeting attendance, voting procedures, and voting results on a specific agenda item (the election of an independent director). It also includes a legal opinion confirming the legality of the meeting and voting process. The document is an official announcement of the voting results from a shareholders' meeting, not the meeting materials or the meeting itself. The length is short (1508 characters) and it focuses on the voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-12 Chinese
北京市通商律师事务所关于瑞普生物股份有限公司2025年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the convening, attendance, and voting procedures of the 2025 second extraordinary general meeting (临时股东大会) of 瑞普生物股份有限公司. It details the meeting notice, attendance, voting methods, vote results, and confirms compliance with relevant laws and company articles. It is not a financial report, earnings release, or management discussion, but a legal opinion on the shareholder meeting process and voting results. This type of document corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and validates the meeting procedures. The document length is 3347 characters, which is consistent with a detailed voting results announcement rather than a full annual report or interim report. Therefore, the correct classification is DVA with high confidence.
2025-05-12 Chinese
关于股份回购完成暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 瑞普生物股份有限公司 regarding the completion of a share repurchase program. It details the number of shares repurchased, the price range, the total amount spent, compliance with regulatory rules, and the intended use of the repurchased shares (employee stock ownership or incentive plans). It also confirms that the repurchase plan has been fully implemented and provides information on the impact on shareholding structure. The document is not a financial report or earnings release but a formal announcement about the company's share buyback activity. According to the filing definitions, this fits the category of 'Transaction in Own Shares' (POS). The document length is 2539 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is POS with high confidence.
2025-04-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.